Levetiracetam Tablet
Product Images NDC 80425-0566

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 80425-0566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam 500mg # 120 (Levetiracetam 500mg 80425 0566 01)

Label for Levetiracetam 500 mg tablet #120 by Advanced Rx of Tennessee, LLC. The label includes NDC 80425-0566-01, a comparison to KEPPRA, lot number placeholder, expiration date 12/31/2030, and source NDC 27808-0264-02 from TRIS PHARMA INC. Storage instructions note to keep between 20° and 25°C.*

FDA Label Image

Levetiracetam 500mg #30 (Levetiracetam 500mg 80425 0566 02)

Label for Levetiracetam 500 mg oral tablets by Advanced Rx of Tennessee, LLC. The label indicates a 30-tablet package with NDC 80425-0566-02. It notes comparison to Keppra, includes lot and expiration date fields (12/31/2030 shown), and storage instructions between 20° and 25°C (68° and 77°F). The label features a barcode and source NDC from Tris Pharma Inc.*

FDA Label Image

Levetiracetam 500mg # 60 (Levetiracetam 500mg 80425 0566 03)

Levetiracetam 500 mg oral tablet label from Advanced Rx of Tennessee, LLC. The label indicates 60 tablets in the package, with storage instructions between 20° and 25°C. It references comparison to Keppra, includes NDC 80425-0566-03, expiration date 12/31/2030, and other lot and source information. The label includes a barcode and company contact details.*

FDA Label Image

Levetiracetam 500mg #90 (Levetiracetam 500mg 80425 0566 04)

Levetiracetam 500 mg tablet packaging label for 90 tablets by Advanced Rx of Tennessee, LLC. The label includes NDC 80425-0566-04, expiration date 12/31/2030, and storage instructions between 20 and 25°C. The label also references comparator product Keppra and source NDC from Tris Pharma Inc.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of levetiracetam, showing its molecular framework with characteristic functional groups including a pyrrolidone ring and an amide side chain.*

FDA Label Image

Figure1 (Levetiracetam Tablets 2)

A bar chart showing the percentage of patients for three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The x-axis lists treatments and sample sizes, while the y-axis indicates the percentage of patients from 0% to 45%.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

A bar graph showing the percentage of patients across three groups: placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Patient numbers for each group are also indicated below the categories.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

A bar chart comparing the percentage of patients responding to Placebo versus Levetiracetam 3000 mg/day. The Placebo group (N=104) shows 14.4%, and the Levetiracetam group (N=180) shows 39.4% of patients, with the Levetiracetam bar significantly higher.*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar chart comparing the percentage of patients for Placebo and Levetiracetam groups. The y-axis represents the percentage of patients, ranging from 0% to 45%. The Placebo group (N=97) shows approximately 19.6% of patients, while the Levetiracetam group (N=101) shows a higher percentage at about 44.6%.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group shows 19.6% while the Levetiracetam group shows 43.1%. Patient numbers are 51 for placebo and 58 for Levetiracetam.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

A vertical bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The Placebo group shows approximately 45.2% of patients, while the Levetiracetam group shows about 72.2% of patients, with asterisk marking significance on the Levetiracetam bar.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.